OBJECTIVE: To test the hypothesis that increasing severity of the fetal inflammatory response (FIR) would have a dose-dependent relationship with severe neurodevelopmental impairment or death in extremely preterm infants. STUDY DESIGN: We report 347 infants of 23-28 weeks gestational age admitted to a tertiary neonatal intensive care unit between 2006 and 2008. The primary outcome was death or neurodevelopmental impairment at the 18- to 22-month follow-up. Exposure status was defined by increasing stage of funisitis (stage 1, phlebitis; stage 2, arteritis with or without phlebitis; stage 3, subacute necrotizing funisitis) and severity of chorionic plate vasculitis (inflammation with or without thrombosis). RESULTS: A FIR was detected in 110 placentas (32%). The rate of severe neurodevelopmental impairment/death was higher in infants with subacute necrotizing funisitis compared with infants without placental/umbilical cord inflammation (60% vs 35%; P < .05). Among infants with stage 1 or 2 funisitis, the presence of any chorionic vasculitis was associated with a higher rate of severe neurodevelopmental impairment/death (47% vs 23%; P < .05). After adjustment for confounding factors, only subacute necrotizing funisitis (risk ratio, 1.87; 95% CI, 1.04-3.35; P = .04) and chorionic plate vasculitis with thrombosis (risk ratio, 2.21; 95% CI, 1.10-4.46; P = .03) were associated with severe neurodevelopmental impairment/death. CONCLUSION: Severe FIR, characterized by subacute necrotizing funisitis and severe chorionic plate vasculitis with thrombosis, is associated with severe neurodevelopmental impairment/death in preterm infants.
OBJECTIVE: To test the hypothesis that increasing severity of the fetal inflammatory response (FIR) would have a dose-dependent relationship with severe neurodevelopmental impairment or death in extremely preterm infants. STUDY DESIGN: We report 347 infants of 23-28 weeks gestational age admitted to a tertiary neonatal intensive care unit between 2006 and 2008. The primary outcome was death or neurodevelopmental impairment at the 18- to 22-month follow-up. Exposure status was defined by increasing stage of funisitis (stage 1, phlebitis; stage 2, arteritis with or without phlebitis; stage 3, subacute necrotizing funisitis) and severity of chorionic plate vasculitis (inflammation with or without thrombosis). RESULTS: A FIR was detected in 110 placentas (32%). The rate of severe neurodevelopmental impairment/death was higher in infants with subacute necrotizing funisitis compared with infants without placental/umbilical cord inflammation (60% vs 35%; P < .05). Among infants with stage 1 or 2 funisitis, the presence of any chorionic vasculitis was associated with a higher rate of severe neurodevelopmental impairment/death (47% vs 23%; P < .05). After adjustment for confounding factors, only subacute necrotizing funisitis (risk ratio, 1.87; 95% CI, 1.04-3.35; P = .04) and chorionic plate vasculitis with thrombosis (risk ratio, 2.21; 95% CI, 1.10-4.46; P = .03) were associated with severe neurodevelopmental impairment/death. CONCLUSION: Severe FIR, characterized by subacute necrotizing funisitis and severe chorionic plate vasculitis with thrombosis, is associated with severe neurodevelopmental impairment/death in preterm infants.
Authors: Jonathan L Hecht; Raina N Fichorova; Vanessa F Tang; Elizabeth N Allred; Thomas F McElrath; Alan Leviton Journal: Pediatr Res Date: 2011-01 Impact factor: 3.756
Authors: Barbara J Stoll; Nellie I Hansen; Edward F Bell; Seetha Shankaran; Abbot R Laptook; Michele C Walsh; Ellen C Hale; Nancy S Newman; Kurt Schibler; Waldemar A Carlo; Kathleen A Kennedy; Brenda B Poindexter; Neil N Finer; Richard A Ehrenkranz; Shahnaz Duara; Pablo J Sánchez; T Michael O'Shea; Ronald N Goldberg; Krisa P Van Meurs; Roger G Faix; Dale L Phelps; Ivan D Frantz; Kristi L Watterberg; Shampa Saha; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2010-08-23 Impact factor: 7.124
Authors: Jonathan L Hecht; Elizabeth N Allred; Harvey J Kliman; Eduardo Zambrano; Barbara J Doss; Aliya Husain; Solveig M V Pflueger; Chung-Ho Chang; Chad A Livasy; Drucilla Roberts; Ina Bhan; Dennis W Ross; Patricia Kaman Senagore; Alan Leviton Journal: Pathology Date: 2008-06 Impact factor: 5.306
Authors: Alan Leviton; Elizabeth N Allred; Karl C K Kuban; Jonathan L Hecht; Andrew B Onderdonk; T Michael O'shea; Nigel Paneth Journal: Pediatr Res Date: 2010-01 Impact factor: 3.756
Authors: William W Andrews; Suzanne P Cliver; Fred Biasini; A Myriam Peralta-Carcelen; Richard Rector; Ann I Alriksson-Schmidt; Ona Faye-Petersen; Waldemar Carlo; Robert Goldenberg; John C Hauth Journal: Am J Obstet Gynecol Date: 2008-04 Impact factor: 8.661
Authors: Karen M Chisholm; Amy Heerema-McKenney; Lu Tian; Anand K Rajani; Suchi Saria; Daphne Koller; Anna A Penn Journal: Placenta Date: 2016-01-16 Impact factor: 3.481
Authors: Augusto F Schmidt; Paranthaman S Kannan; Claire A Chougnet; Steve C Danzer; Lisa A Miller; Alan H Jobe; Suhas G Kallapur Journal: J Neuroinflammation Date: 2016-09-06 Impact factor: 8.322
Authors: Shenandoah Robinson; Fatu S Conteh; Akosua Y Oppong; Tracylyn R Yellowhair; Jessie C Newville; Nagat El Demerdash; Christine L Shrock; Jessie R Maxwell; Stephen Jett; Frances J Northington; Lauren L Jantzie Journal: Front Cell Neurosci Date: 2018-09-25 Impact factor: 5.505